ECSP19035377A - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- ECSP19035377A ECSP19035377A ECSENADI201935377A ECDI201935377A ECSP19035377A EC SP19035377 A ECSP19035377 A EC SP19035377A EC SENADI201935377 A ECSENADI201935377 A EC SENADI201935377A EC DI201935377 A ECDI201935377 A EC DI201935377A EC SP19035377 A ECSP19035377 A EC SP19035377A
- Authority
- EC
- Ecuador
- Prior art keywords
- magl inhibitors
- compositions
- magl
- useful
- compounds
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title abstract 2
- 101710116393 Monoglyceride lipase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- CWPIBZMCMRNFHK-UHFFFAOYSA-N piperazin-1-ium;carbamate Chemical class NC(O)=O.C1CNCCN1 CWPIBZMCMRNFHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan en este documento carbamatos de piperazina y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones objeto son útiles como moduladores de MAGL. Adicionalmente, los compuestos y composiciones objeto son útiles para el tratamiento del dolor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423095P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19035377A true ECSP19035377A (es) | 2019-05-31 |
Family
ID=62107273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201935377A ECSP19035377A (es) | 2016-11-16 | 2019-05-17 | Inhibidores de magl |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9981930B1 (es) |
| EP (1) | EP3541822B1 (es) |
| JP (1) | JP6987859B2 (es) |
| KR (1) | KR20190077087A (es) |
| CN (1) | CN110248947B (es) |
| AR (1) | AR110088A1 (es) |
| AU (1) | AU2017361250A1 (es) |
| BR (1) | BR112019009991A2 (es) |
| CA (1) | CA3043612A1 (es) |
| CL (1) | CL2019001335A1 (es) |
| CO (1) | CO2019005038A2 (es) |
| CR (1) | CR20190243A (es) |
| DO (1) | DOP2019000121A (es) |
| EA (1) | EA201991074A1 (es) |
| EC (1) | ECSP19035377A (es) |
| ES (1) | ES2908632T3 (es) |
| IL (1) | IL266550A (es) |
| JO (1) | JOP20190105A1 (es) |
| MA (1) | MA46860A (es) |
| MX (1) | MX2019005771A (es) |
| NI (1) | NI201900050A (es) |
| PE (1) | PE20191146A1 (es) |
| PH (1) | PH12019501102A1 (es) |
| RU (1) | RU2019116514A (es) |
| TN (1) | TN2019000150A1 (es) |
| TW (1) | TW201831458A (es) |
| WO (1) | WO2018093946A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013207252B2 (en) | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
| AU2016262459A1 (en) | 2015-05-11 | 2017-12-21 | H. Lundbeck A/S. | Methods of treating inflammation or neuropathic pain |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| UA124585C2 (uk) | 2016-11-16 | 2021-10-13 | Лундбек Ла Джолла Ресеарч Центер, Інк. | Кристалічні форми інгібітора magl |
| PE20200664A1 (es) | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
| US11267825B2 (en) * | 2017-11-02 | 2022-03-08 | Aicuris Gmbh & Co. Kg | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) |
| EP3793547A4 (en) | 2018-05-15 | 2021-11-17 | H. Lundbeck A/S | MAGL INHIBITORS |
| EP4139288A1 (en) * | 2020-04-21 | 2023-03-01 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CA3250023A1 (en) | 2022-05-04 | 2023-11-09 | H. Lundbeck A/S | CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZINE-3-YLCARBAMOYL)-6 AZASPIRO[2,5]OCTANE-6-CARBOXYLATE AS A MONOACYLGLYCEROL LIPASE INHIBITOR |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (es) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| DE69211015T2 (de) | 1991-11-27 | 1997-01-09 | Du Pont | Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate |
| JPH09506920A (ja) | 1993-12-22 | 1997-07-08 | シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー | カルバメートの製造法 |
| JP2000500448A (ja) | 1995-11-15 | 2000-01-18 | ゼネカ リミテッド | 除草性置換ピラゾール化合物 |
| WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| CA2386239A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying rna binding compounds |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
| CN1934097A (zh) | 2004-02-18 | 2007-03-21 | 阿斯利康(瑞典)有限公司 | 炔基化哌嗪化合物及其作为代谢型谷氨酸受体拮抗剂的应用 |
| AU2005233125A1 (en) * | 2004-04-07 | 2005-10-27 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| CN101087786A (zh) | 2004-12-23 | 2007-12-12 | 霍夫曼-拉罗奇有限公司 | 杂环氨基甲酸酯衍生物，它们的制备及作为药剂的应用 |
| DK1836179T3 (en) | 2004-12-30 | 2015-05-26 | Janssen Pharmaceutica Nv | PIPERIDINE AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FAT ACID AMIDE HYDRALASE (FAAH) FOR THE TREATMENT OF ANCIENT, PAIN AND OTHER CONDITIONS |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| EP1987037A2 (en) | 2006-02-23 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| JP2010519337A (ja) | 2007-02-26 | 2010-06-03 | コーサン バイオサイエンシーズ， インコーポレイテッド | カルバメート化合物 |
| JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Ｈｄｌ上昇剤 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| AU2009270983A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and their use as GPCR modulators |
| CA2743861A1 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| AU2010229134A1 (en) | 2009-03-23 | 2011-11-10 | Msd K.K. | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| EP2497082B1 (de) | 2009-11-03 | 2013-09-04 | Bayer Intellectual Property GmbH | Fluorurethane als additive in einer photopolymer-formulierung |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| AU2013207252B2 (en) | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
| UA117451C2 (uk) | 2012-01-06 | 2018-08-10 | Аджиос Фармасьютікалз, Інк. | Терапевтично активні сполуки і способи їх застосування |
| MX2014011134A (es) * | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos. |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| MX2015017961A (es) | 2013-07-03 | 2016-10-14 | Abide Therapeutics Inc | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
| CA2979537C (en) | 2015-03-18 | 2023-08-29 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| AU2016262459A1 (en) * | 2015-05-11 | 2017-12-21 | H. Lundbeck A/S. | Methods of treating inflammation or neuropathic pain |
| WO2017143283A1 (en) * | 2016-02-19 | 2017-08-24 | Abide Therapeutics, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| ES2861648T3 (es) * | 2016-05-12 | 2021-10-06 | Lundbeck La Jolla Research Center Inc | Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
-
2017
- 2017-06-16 JO JOP/2019/0105A patent/JOP20190105A1/ar unknown
- 2017-11-15 EA EA201991074A patent/EA201991074A1/ru unknown
- 2017-11-15 AU AU2017361250A patent/AU2017361250A1/en not_active Abandoned
- 2017-11-15 BR BR112019009991A patent/BR112019009991A2/pt not_active Application Discontinuation
- 2017-11-15 CR CR20190243A patent/CR20190243A/es unknown
- 2017-11-15 CN CN201780083635.4A patent/CN110248947B/zh not_active Expired - Fee Related
- 2017-11-15 RU RU2019116514A patent/RU2019116514A/ru not_active Application Discontinuation
- 2017-11-15 WO PCT/US2017/061867 patent/WO2018093946A1/en not_active Ceased
- 2017-11-15 CA CA3043612A patent/CA3043612A1/en not_active Abandoned
- 2017-11-15 AR ARP170103183A patent/AR110088A1/es unknown
- 2017-11-15 MA MA046860A patent/MA46860A/fr unknown
- 2017-11-15 JP JP2019523589A patent/JP6987859B2/ja not_active Expired - Fee Related
- 2017-11-15 PE PE2019001015A patent/PE20191146A1/es unknown
- 2017-11-15 KR KR1020197016859A patent/KR20190077087A/ko not_active Withdrawn
- 2017-11-15 ES ES17871883T patent/ES2908632T3/es active Active
- 2017-11-15 US US15/814,318 patent/US9981930B1/en active Active
- 2017-11-15 TN TNP/2019/000150A patent/TN2019000150A1/en unknown
- 2017-11-15 MX MX2019005771A patent/MX2019005771A/es unknown
- 2017-11-15 EP EP17871883.9A patent/EP3541822B1/en active Active
- 2017-11-16 TW TW106139750A patent/TW201831458A/zh unknown
-
2019
- 2019-05-12 IL IL266550A patent/IL266550A/en unknown
- 2019-05-16 NI NI201900050A patent/NI201900050A/es unknown
- 2019-05-16 CO CONC2019/0005038A patent/CO2019005038A2/es unknown
- 2019-05-16 PH PH12019501102A patent/PH12019501102A1/en unknown
- 2019-05-16 CL CL2019001335A patent/CL2019001335A1/es unknown
- 2019-05-16 DO DO2019000121A patent/DOP2019000121A/es unknown
- 2019-05-17 EC ECSENADI201935377A patent/ECSP19035377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6987859B2 (ja) | 2022-01-05 |
| DOP2019000121A (es) | 2019-09-30 |
| TN2019000150A1 (en) | 2020-10-05 |
| CA3043612A1 (en) | 2018-05-24 |
| PE20191146A1 (es) | 2019-09-02 |
| CO2019005038A2 (es) | 2019-05-31 |
| RU2019116514A (ru) | 2020-12-17 |
| AU2017361250A1 (en) | 2019-05-30 |
| US20180134675A1 (en) | 2018-05-17 |
| NI201900050A (es) | 2019-10-30 |
| AR110088A1 (es) | 2019-02-20 |
| PH12019501102A1 (en) | 2019-08-19 |
| BR112019009991A2 (pt) | 2019-08-27 |
| EP3541822A1 (en) | 2019-09-25 |
| CN110248947A (zh) | 2019-09-17 |
| JOP20190105A1 (ar) | 2019-05-09 |
| JP2020502047A (ja) | 2020-01-23 |
| KR20190077087A (ko) | 2019-07-02 |
| CR20190243A (es) | 2019-06-26 |
| CN110248947B (zh) | 2022-04-01 |
| EA201991074A1 (ru) | 2019-12-30 |
| IL266550A (en) | 2019-07-31 |
| EP3541822A4 (en) | 2020-04-29 |
| MA46860A (fr) | 2019-09-25 |
| TW201831458A (zh) | 2018-09-01 |
| EP3541822B1 (en) | 2022-01-19 |
| MX2019005771A (es) | 2019-12-05 |
| WO2018093946A1 (en) | 2018-05-24 |
| CL2019001335A1 (es) | 2019-10-04 |
| ES2908632T3 (es) | 2022-05-03 |
| US9981930B1 (en) | 2018-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900051A (es) | Inhibidores de magl | |
| ECSP19035377A (es) | Inhibidores de magl | |
| NI202000080A (es) | Inhibidores de magl | |
| ECSP19083923A (es) | Inhibidores pirazólicos de magl | |
| NI201900049A (es) | Inhibidores de la magl | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2019003397A1 (es) | Inhibidores pirazólicos de magl. | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |